Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1902449 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNN4KDM1AHSD17B2RIPK1 | |
| SCHEMBL29897574 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNN4KDM1AHSD17B2RIPK1 | |
| SCHEMBL12490813 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNN4KDM1AHSD17B2RIPK1 | |
| SCHEMBL16134334 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNN4KDM1AHSD17B2RIPK1 | |
| SCHEMBL12524313 | 1.00 | SIGMAR1 (1.00) | SIGMAR1KCNN4KDM1AHSD17B2RIPK1 | |
| SCHEMBL12491341 | 0.88 | SIGMAR1 (0.79) | SIGMAR1HSD17B2RIPK1 | |
| SCHEMBL1904422 | 0.88 | SIGMAR1 (0.79) | SIGMAR1HSD17B2RIPK1 | |
| SCHEMBL11993135 | 0.87 | SIGMAR1 (0.77) | SIGMAR1HSD17B2RIPK1 | |
| SCHEMBL1904928 | 0.81 | SIGMAR1 (0.68) | SIGMAR1ALDH1A1 | |
| SCHEMBL12491087 | 0.81 | SIGMAR1 (0.68) | SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4523686-A1 | A SIGMA-1 RECEPTOR POSITIVE MODULATOR FOR ITS USE IN THE PREVENTION AND THE TREATMENT OF A PATHOLOGY | UNIVERSITE DE MONTPELLIER (FR) | 2025-03-19 | — | — | EP | disclosed |
| US-20240299317-A1 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | ZOGENIX INTERNATIONAL LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| WO-2023101866-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |
| US-20230165810-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| WO-2023006412-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | UNIVERSITÉ DE MONTPELLIER (FR) | 2023-02-02 | — | — | WO | disclosed |
| EP-4124338-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | Université de Montpellier (FR) | 2023-02-01 | — | — | EP | disclosed |
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2014-10-02 | — | — | US | disclosed |
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2014-10-02 | — | — | US | disclosed |
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2014-10-02 | — | — | US | disclosed |
| US-8791273-B2 | 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | JSC GRINDEKS (LV) | 2014-07-29 | — | — | US | disclosed |
| EP-2496555-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | Grindeks, A Joint Stock Company (LV) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496555-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | Grindeks, A Joint Stock Company (LV) | 2012-09-12 | — | — | EP | disclosed |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2012-08-23 | — | — | US | disclosed |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2012-08-23 | — | — | US | disclosed |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2012-08-23 | — | — | US | disclosed |
| CN-102596905-A | 4R, 5S-enantiomer of 2- (5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl) -acetamide with nootropic activity | GRINDEKS JSC | 2012-07-18 | — | — | CN | disclosed |
| CN-102596905-A | 4R, 5S-enantiomer of 2- (5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl) -acetamide with nootropic activity | GRINDEKS JSC | 2012-07-18 | — | — | CN | disclosed |
| WO-2011054888-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054888-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054888-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165810-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | SIGMAR1, HTR1A, HTR1E | SIGMAR1 1/4885KCNN4 243/4885KDM1A 1742/4885 |
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | SIGMAR1 188/4885KCNN4 264/4885KDM1A 799/4885 |
| US-20240299317-A1 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | SIGMAR1, HTR1A, HTR1E | SIGMAR1 1/4885KCNN4 243/4885KDM1A 1742/4885 |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | SIGMAR1 188/4885KCNN4 264/4885KDM1A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.